LifeTech Scientific Corporation
先健科技公司

(Incorporated in the Cayman Islands with limited liability)
(Stock code: 1302)

VOLUNTARY ANNOUNCEMENT

Publication of the One-Year Follow-Up Results of Phase III Clinical Study of IBS® Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System

This announcement is made by LifeTech Scientific Corporation (the "**Company**", together with its subsidiaries, the "**Group**") on a voluntary basis to provide its shareholders and potential investors with information in relation to the latest business and new product development of the Group.

The board (the "**Board**") of directors (the "**Directors**") of the Company is pleased to announce that the one-year follow-up of the phase III clinical study (the "**Phase III Clinical Study**") on the Group's self-developed IBS® Sirolimus-Eluting Iron Bioresorbable Coronary Scaffold System ("**IBS® Coronary Scaffold**" or the "**Product**") has been successfully completed, and the one-year primary endpoint follow-up results of IBS® Coronary Scaffold Phase III Clinical Study were announced globally for the first time by Dr. Lei Song (宋雷), the director of Fuwai Hospital, Chinese Academy of Medical Sciences, on behalf of Academician Runlin Gao (高潤霖) and entire research and development team, at the Transcatheter Cardiovascular Therapeutics (TCT) 2024 on 29 October 2024 local time in the United States.

The Phase III Clinical Study on IBS® Coronary Scaffold is a prospective, multi-center, single-arm clinical trial. The primary endpoint of the study was the Target Lesion Failure (TLF) one year after the implantation of IBS® Coronary Scaffold, and the Phase III Clinical Study was officially launched in February 2023. A total of 1,061 patients were enrolled for the Phase III Clinical Study, including more than 200 subjects whom implanted IBS® Coronary Scaffold in the IBS randomized controlled study ("**Phase II Clinical Study**") and over 800 subjects

enrolled separately for Phase III Clinical Study. These over 800 newly subjects were successfully enrolled within five months in 27 domestic centers. The one-year clinical follow-up results showed that one year after the implantation of IBS® Coronary Scaffold, the target lesion failure (TLF) was 2.9%, cardiac death was 0%, target vessel myocardial infarction was 1.1%, and the incidence of thrombotic events was 0.4% (all the incidence of thrombotic events occurring within 1 month), which further proves its remarkable performance in terms of safety and effectiveness.

IBS® Coronary Scaffold is the world's first iron-based bioresorbable coronary scaffold, as far as the Company is aware. The backbone is processed from high-purity nitrided iron pipes with high strength and plasticity, and the strut is thin with a high radial strength. The innovative material research and unique technological approach enable the Product to retain the advantages of permanent metal coronary stents, namely complete specifications, superior physical properties, good biocompatibility, simple operation and has fully absorbable characteristics, thereby effectively avoiding a series of long-term prognosis issues that may arise from the implantation of permanent metal stents.

The announcement of the one-year follow-up results of the Phase III Clinical Study of IBS® Coronary Scaffold further enhances the evidence-based medical evidences for this innovative product and will lay a solid foundation for the global development of the Product and other core products on our iron-based bioresorbable material platform. Currently, IBS® Coronary Scaffold has been successfully submitted for CE registration approval and is expected successfully commercialized in European Union. With the steady progress of follow-up clinical trials, more evidence-based medical evidences are expected to further confirm the safety and effectiveness of the Product. The Company believes that when it is launched to the market, IBS® Coronary Scaffold will bring unprecedented treatment for patients with coronary heart disease all over the world.

By order of the Board
LifeTech Scientific Corporation
XIE Yuehui
Executive Director, Chairman and Chief Executive Officer

Hong Kong, 31 October 2024

As at the date of this announcement, the Board comprises Mr. XIE Yuehui and Mr. LIU Jianxiong being executive Directors; Mr. JIANG Feng being non-executive Director; and Mr. LIANG Hsien Tse Joseph, Mr. WANG Wansong and Mr. ZHOU Luming being independent non-executive Directors.